Business Context and Reporting Period
This Form 8-K is a current report filed by Integrity Applications, Inc. (not Glucotrack, Inc.) on September 7, 2016, regarding events occurring on August 31, 2016. The filing details the fifth closing of a private placement offering of Series C Convertible Preferred Stock and associated warrants to accredited investors.
Key Financial Metrics
- Gross Proceeds: $540,000 received from the sale of 540 Units in this closing.
- Capital Structure Impact: Issuance of 540 shares of Series C 5.5% Convertible Preferred Stock.
- Conversion Terms: Preferred Stock converts to Common Stock at an initial price of $4.50 per share (totaling 120,003 shares).
- Warrant Terms: Two sets of 5-year warrants issued per unit:
- Series C-1: Exercise price $4.50 per share.
- Series C-2: Exercise price $7.75 per share.
- Total Warrant Coverage: Warrants are exercisable for an aggregate of 240,006 shares of Common Stock.
- Placement Agent Compensation: 10% commission plus 3% expense allowance on gross proceeds, plus warrants for 36,001 shares of Common Stock.
Material Changes
This transaction represents the fifth closing of an ongoing offering. Previous closings (April through July 2016) involved the sale of 4,425.15 Units. The terms of the Preferred Stock and Warrants in this closing are identical to those in prior issuances. The filing does not provide comparative financial statements or changes in revenue, profit, or cash flow for the period.
Outlook, Risks, and Contingencies
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the securities were sold unregistered under Section 4(a)(2) of the Securities Act of 1933. The Placement Agent warrants include full ratchet anti-dilution protection and cashless exercise options, which may impact future equity dilution.
Investor Verification Checklist
- Verify the total aggregate capital raised across all five closings of this offering.
- Confirm the current outstanding share count of Common Stock to assess the dilution impact of the 120,003 convertible shares and 240,006 warrant shares.
- Review the "Prior 8-Ks" (filed April 14, May 4, June 6, and July 7, 2016) for the full terms of the Securities Purchase Agreement and Registration Rights Agreement.
- Assess the company's cash runway given the $540,000 gross proceeds and the 13% total cost of capital (10% commission + 3% expenses) paid to the placement agent.